IGKV2D-29 and Parkinson disease: Besides, vipadenant also belongs to a group of potent A2A antagonists, which was used for the treatment of PD (Pourcher and Huot, 2015), but its development was stopped due to safety concerns and later switched to cancer immunotherapy (Yu et al., 2020).